Glucosuria associated with SGLT2 inhibitor adherence and clinical outcomes in observational real-world study
This observational study examined whether urinary glucose (glucosuria) could serve as a marker of adherence to SGLT2 inhibitors and whether it correlated with clinical outcomes in routine clinical practice. No sample size or effect sizes were reported in the available information.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 17, 2026 · Discovered: Sep 17, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Cohort
- Sample size
- 45,711
- Duration
- 40 months
- Population
- Cohort 2 comprised 45,711 patients prescribed SGLT2 inhibitors with urinalysis performed within 6 months after initiation, from the Optum Labs Data Warehouse real-world data (2014-2023)
- Primary outcome
- All-cause mortality
- Effect size
- All-cause mortality: HR 0.78 (95% CI 0.73-0.83); Heart failure hospitalization: HR 0.87 (95% CI 0.78-0.98); End-stage kidney disease: HR 0.73 (95% CI 0.58-0.91); Fractures: HR 1.00 (95% CI 0.95-1.06)
- Significance
- Mixed
- Journal
- Journal of the American Society of Nephrology (JASN)
- Published
- Sep 17, 2026
Sources
Primary source
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.